PET in the management of locally advanced and metastatic NSCLC

Nature Reviews Clinical Oncology

Volumn 12, Issue 7, 2015, Pages 395-407

  Grootjans, Willem ^a   De Geus Oei, Lioe Fee ^b   Troost, Esther G C ^c   Visser, Eric P ^a   Oyen, Wim J G ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CARBOPLATIN; CRIZOTINIB; DOCETAXEL; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GLUCOSE TRANSPORTER 1; IRINOTECAN; KI 67 ANTIGEN; NAVELBINE; PACLITAXEL; THYMIDINE KINASE 1;

ADAPTATION; ADVANCED CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; DIAGNOSTIC IMAGING; DISEASE SPECIFIC SURVIVAL; DNA FRAGMENTATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMAGE GUIDED RADIOTHERAPY; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LOCAL METASTASIS; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE METASTASIS; METASTASIS FREE SURVIVAL; METASTASIS POTENTIAL; MOLECULAR IMAGING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REVIEW; SIGNAL TRANSDUCTION; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED RADIOTHERAPY; DISEASE MANAGEMENT; LUNG NEOPLASMS; PATHOLOGY; PATIENT CARE; PATIENT SELECTION; PROCEDURES; SCINTISCANNING; SECONDARY;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MANAGEMENT; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PATIENT SELECTION; PATIENT-CENTERED CARE; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84933278307     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.75     Document Type: Review

References (127)

1. Jemal A., et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011
2. Molina J. R., Yang P., Cassivi S. D., Schild S. E. & Adjei A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584-594 (2008
3. Shepherd F. A., et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J. Thorac. Oncol. 2, 1067-1077 (2007
4. Aupérin A., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non small cell lung cancer. J. Clin. Oncol. 28, 2181-2190 (2010
5. Maemondo M., et al. Gefitinib or chemotherapy for non small cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010
6. Giaccone G., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non small cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 22, 777-784 (2004
7. Herbst R. S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non small cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 22, 785-794 (2004
8. Govindan R., et al. Genomic landscape of non small cell lung cancer in smokers and never smokers. Cell 150, 1121-1134 (2012
9. Kaira K., et al. Biological significance of 18F FDG uptake on PET in patients with non small cell lung cancer. Lung Cancer 83, 197-204 (2014
10. Hellwig D., Baum R. P. & Kirsch C. M. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer-a systematic review. Nuklearmedizin 48, 59-69 (2009
11. van Tinteren H., et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non small cell lung cancer: the PLUS multicentre randomised trial. Lancet 359, 1388-1392 (2002
12. Mac Manus M. P., et al. The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data. Radiother. Oncol. 106, 292-298 (2013
13. Tehrani O. S. & Shields A. F. PET imaging of proliferation with pyrimidines. J. Nucl. Med. 54, 903-912 (2013
14. Shields A. F., et al. Imaging proliferation in vivo with [F 18]FLT and positron emission tomography. Nat. Med. 4, 1334-1336 (1998
15. Chalkidou A., et al. Correlation between Ki 67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur. J. Cancer 48, 3499-3513 (2012
16. Buck A., et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur. J. Nucl. Med. Mol. Imaging 32, 525-533 (2005
17. Yamamoto Y., et al. Comparison of 18F-FLT PET and 18F-FDG PET for preoperative staging in non small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 236-245 (2008
18. Cobben D. C., et al. Is 18F 3′ fluoro 3′ deoxy L-thymidine useful for the staging and restaging of non-small cell lung cancer?. J. Nucl. Med. 45, 1677-1682 (2004
19. Vansteenkiste J., et al. Early and locally advanced non small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24, vi89-vi98 (2013
20. O'Rourke N., Roqué i Figuls M., Farré Bernadó N. & Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database of Systematic Reviews, Issue 6. Art. No.: CD002140. http://dx.doi.org/10.1002/14651858.CD002140.pub3 (2010
21. Curran W. J., et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J. Natl Cancer Inst. 103, 1452-1460 (2011
22. Goffin J., et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J. Thorac. Oncol. 5, 260-274 (2010
23. Albain K. S., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non small cell lung cancer: a phase III randomised controlled trial. Lancet 374, 379-386 (2009
24. Machtay M., et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J. Thorac. Oncol. 7, 716-722 (2012
25. Hanahan D. & Weinberg R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
26. Junttila M. R. & De Sauvage F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354 (2013
27. Fidler I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458 (2003
28. Schiller J. H., et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002
29. Baumann M., Krause M. & Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8, 545-554 (2008
30. Baumann M., et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non small cell lung cancer (NSCLC). Radiother. Oncol. 100, 76-85 (2011
31. Mauguen A., et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J. Clin. Oncol. 30, 2788-2797 (2012
32. Everitt S. J., et al. Differential 18F-FDG and 18F-FLT uptake on serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer. J. Nucl. Med. 55, 1069-1074 (2014
33. Yue J. B., et al. Histopathologic validation of 3′ deoxy 3′ 18F fluorothymidine PET for detecting tumor repopulation during fractionated radiotherapy of human FaDu squamous cell carcinoma in nude mice. Radiother. Oncol. 111, 475-481 (2014
34. Graves E. E., Maity A. & Le Q. T. The tumor microenvironment in non small cell lung cancer. Semin. Radiat. Oncol. 20, 156-163 (2010
35. Bollineni V. R., Wiegman E. M., Pruim J., Groen H. J. M. & Langendijk J. A. Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy. Cancer Treat. Rev. 38, 1027-1032 (2012
36. Horsman M. R., Mortensen L. S., Petersen J. B., Busk M. & Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat. Rev. Clin. Oncol. 9, 674-687 (2012
37. Sun X., Niu G., Chan N., Shen B. & Chen X. Tumor hypoxia imaging. Mol. Imaging Biol. 13, 399-410 (2011
38. Hu M., et al. Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer. Clin. Nucl. Med. 38, 91-596 (2013
39. Zegers C. M., et al. Hypoxia imaging with [18F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother. Oncol. 109, 58-64 (2013
40. Postema E., et al. Initial results of hypoxia imaging using 1 a d (5 deoxy 5-18F-fluoroarabinofuranosyl) 2 nitroimidazole (18F-FAZA). Eur. J. Nucl. Med. Mol. Imaging 36, 1565-1573 (2009
41. Dehdashti F., et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur. J. Nucl. Med. Mol. Imaging 30, 844-850 (2003
42. Yip C., Blower P., Goh V., Landau D. & Cook G. R. Molecular imaging of hypoxia in non small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 42, 956-976 (2015
43. Meng X., Kong F. M. & Yu J. Implementation of hypoxia measurement into lung cancer therapy. Lung Cancer 75, 146-150 (2012
44. Williamson S. K., et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non small cell lung cancer: Southwest Oncology Group Trial S0003. J. Clin. Oncol. 23, 9097-9104 (2005
45. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [online], http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf (2010
46. Leimgruber A., et al. Effect of platinum-based chemoradiotherapy on cellular proliferation in bone marrow and spleen, estimated by 18F-FLT PET/CT in patients with locally advanced non small cell lung cancer. J. Nucl. Med. 55, 1075-1080 (2014
47. Kocak Z., et al. Prospective assessment of dosimetric/physiologic-based models for predicting radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 67, 178-186 (2007
48. Petit S. F., et al. [18F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non small cell lung cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 81, 698-705 (2011
49. Castillo R., et al. Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. Radiat. Oncol. 9, 74 (2014
50. Mac Manus M. P., et al. Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non small cell lung cancer and radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 80, 1365-1371 (2011
51. De Ruysscher D., Nestle U., Jeraj R. & MacManus M. PET scans in radiotherapy planning of lung cancer. Lung Cancer 75, 141-145 (2012
52. van Baardwijk A., et al. PET CT based auto contouring in non small cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int. J. Radiat. Oncol. Biol. Phys. 68, 771-778 (2007
53. De Ruysscher D., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non small cell lung cancer: a prospective clinical study. Int. J. Radiat. Oncol. Biol. Phys. 62, 988-994 (2005
54. Bentzen S. M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 6, 112-117 (2005
55. Aerts H. J., et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG PET CT scan: a prospective validation. Lung Cancer 75, 73-76 (2012
56. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01024829 (2014
57. van Elmpt W., et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother. Oncol. 104, 67-71 (2012
58. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02354274 (2015
59. Sonke J. J. & Belderbos J. Adaptive radiotherapy for lung cancer. Semin. Radiat. Oncol. 20, 94-106 (2010
60. Guckenberger M., Wilbert J., Richter A., Baier K. & Flentje M. Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 79, 901-908 (2011
61. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01507428 (2015
62. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01207063 (2014
63. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01190527 (2015
64. Eisenhauer E. A., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009
65. Wahl R. L., Jacene H., Kasamon Y. & Lodge M. A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122S-150S (2009
66. Huang W., et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J. Nucl. Med. 55, 1584-1590 (2014
67. Usmanij E. A., et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J. Nucl. Med. 54, 1528-1534 (2013
68. Decoster L., et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 62, 55-61 (2008
69. Trigonis I., et al. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non small cell lung cancer (NSCLC) treated with radiotherapy alone. Eur. J. Nucl. Med. Mol. Imaging 41, 682-693 (2014
70. Kahraman D., et al. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3′ deoxy 3′ 18F fluorothymidine PET. J. Nucl. Med. 52, 1871-1877 (2011
71. Sohn H. J., et al. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin. Cancer Res. 14, 7423-7429 (2008
72. Zander T., et al. Early prediction of nonprogression in advanced non small cell lung cancer treated with erlotinib by using [18F]fluorodeoxyglucose and [18F]fluorothymidine positron emission tomography. J. Clin. Oncol. 29, 1701-1708 (2011
73. Yoon D. H., et al. FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy. Clin. Cancer Res. 17, 5093-5100 (2011
74. Moon S., et al. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. Eur. J. Nucl. Med. Mol. Imaging 40, 1005-1013 (2013
75. Lopez Guerra J. L., et al. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer. 53, 225-233 (2012
76. Machtay M., et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non small cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J. Clin. Oncol. 31, 3823-3830 (2013
77. Chen H. H., Chiu N. T., Su W. C., Guo H. R. & Lee B. F. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 264, 559-566 (2012
78. Liao S., et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 39, 27-38 (2012
79. Im H. J., et al. Prognostic value of volumetric parameters of 18F-FDG PET in non small cell lung cancer: a meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 42, 241-251 (2015
80. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/study/NCT00564733 (2013
81. Hicks R. J. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J. Nucl. Med. 50, 31S-42S (2009
82. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J. Nucl. Med. 50, 11S-20S (2009
83. Boellaard R., et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging 42, 328-354 (2015
84. Korreman S. S. Motion in radiotherapy: photon therapy. Phys. Med. Biol. 57, R161-R191 (2012
85. Dawood M., Büther F., Lang N., Schober O. & Schäfers K. P. Respiratory gating in positron emission tomography: a quantitative comparison of different gating schemes. Med. Phys. 34, 3067-3076 (2007
86. Grootjans W., et al. Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. Eur. Radiol. 24, 3242-3250 (2014
87. Büther F., et al. List mode-driven cardiac and respiratory gating in PET. J. Nucl. Med. 50, 674-681 (2009
88. Bundschuh R. A., et al. Postacquisition detection of tumor motion in the lung and upper abdomen using list-mode pet data: a feasibility study. J. Nucl. Med. 48, 758-763 (2007
89. Kesner A. L. & Kuntner C. A new fast and fully automated software based algorithm for extracting respiratory signal from raw PET data and its comparison to other methods. Med. Phys. 37, 5550-5559 (2010
90. Houshmand S., et al. An update on novel quantitative techniques in the context of evolving whole-body PET imaging. PET Clinics 10, 45-58 (2015
91. Hoetjes N. J., et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur. J. Nucl. Med. Mol. Imaging 37, 1679-1687 (2010
92. Tixier F., et al. Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer. J. Nucl. Med. 55, 1235-1241 (2014
93. Cook G. J., et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?. J. Nucl. Med. 54, 19-26 (2013
94. Houseni M., et al. Prognostic implication of dual phase PET in adenocarcinoma of the lung. J. Nucl. Med. 51, 535-542 (2010
95. Chen H. H., et al. The increment in standardized uptake value determined using dual-phase 18F FDG PET is a promising prognostic factor in non small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 40, 1478-1485 (2013
96. Schmidt-Hansen M., Baldwin D. R. & Hasler E. What is the most effective follow-up model for lung cancer patients?. A systematic review. J. Thorac. Oncol. 7, 821-824 (2012
97. Ettinger D. S., et al. Non-small cell lung cancer. J. Natl Compr. Canc. Netw. 10, 1236-1271 (2012
98. Mac Manus M. P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non small cell lung cancer. J. Clin. Oncol. 21, 1285-1292 (2003
99. van Loon J., et al. Follow-up with 18FDG PET CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur. J. Cancer 45, 588-595 (2009
100. Hicks R. J., et al. The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J. Nucl. Med. 42, 1605-1613 (2001
101. Antoniou A. J., Marcus C., Tahari A. K., Wahl R. L. & Subramaniam R. M. Follow-up or surveillance 18F FDG PET/CT and survival outcome in lung cancer patients. J. Nucl. Med. 55, 1062-1068 (2014
102. van Der Veldt A. A., Smit E. F. & Lammertsma A. A. Positron emission tomography as a method for measuring drug delivery to tumors in vivo: the example of [11C]docetaxel. Front. Oncol. 3, 208 (2013
103. van Der Veldt A. A., et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [11C]docetaxel and positron emission tomography. Clin. Cancer Res. 19, 4163-4173 (2013
104. van Der Veldt A. A., et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21, 82-91 (2012
105. Zhou C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non small cell lung cancer (OPTIMAL, CTONG 0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011
106. van De Wateringen F. C., et al. Zirconium 89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed. Res. Int. 2014, 203601 (2014
107. Memon A. A., et al. PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br. J. Cancer 105, 1850-1855 (2011
108. Meng X., et al. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J. Nucl. Med. 52, 1573-1579 (2011
109. Kwak E. L., et al. anaplastic lymphoma kinase inhibition in non small cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010
110. Bergethon K., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012
111. Gold K. A. ROS1-targeting the one percent in lung cancer. N. Engl. J. Med. 371, 2030-2031 (2014
112. Shaw A. T., et al. Crizotinib in ROS1-rearranged non small cell lung cancer. N. Engl. J. Med. 371, 1963-1971 (2014
113. Shaw A. T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013
114. Stollman T. H., Ruers T. J., Oyen W. J. & Boerman O. C. New targeted probes for radioimaging of angiogenesis. Methods 48, 188-192 (2009
115. Gaertner F. C., Kessler H., Wester H. J., Schwaiger M. & Beer A. J. Radiolabelled RGD peptides for imaging and therapy. Eur. J. Nucl. Med. Mol. Imaging 39, 126-138 (2012
116. Beer A. J., et al. Comparison of integrin avβ3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F Galacto RGD and 18F-FDG. J. Nucl. Med. 49, 22-29 (2008
117. Shimizu K., et al. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non small cell lung cancer. Br. J. Cancer 110, 2030-2039 (2014
118. Pieterman R., et al. Visualisation and assessment of the protein synthesis rate of lung cancer using carbon 11 tyrosine and positron emission tomography. Eur. J. Nucl. Med. 29, 243-247 (2002
119. Pauleit D., et al. PET with O-(2-18F-fluoroethyl)-L-tyrosine in peripheral tumors: first clinical results. J. Nucl. Med. 46, 411-416 (2005
120. Miyazawa H., Arai T., Iio M. & Hara T. PET imaging of non small cell lung carcinoma with carbon 11 methionine: relationship between radioactivity uptake and flow-cytometric parameters. J. Nucl. Med. 34, 1886-1891 (1993
121. Kaira K., et al. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J. Nucl. Med. 50, 1770-1776 (2009
122. Kaira K., et al. Assessment of therapy response in lung cancer with 18F a-methyl tyrosine PET. AJR Am. J. Roentgenol. 195, 1204-1211 (2010
123. Baek S., et al. Exploratory clinical trial of (4S) 4 (3 [18F]fluoropropyl) L glutamate for imaging xC transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin. Cancer Res. 18, 5427-5437 (2012
124. Huang C. & McConathy J. Radiolabeled amino acids for oncologic imaging. J. Nucl. Med. 54, 1007-1010 (2013
125. Neves A. A. & Brindle K. M. Imaging cell death. J. Nucl. Med. 55, 1-4 (2014
126. Allen A., et al. Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F ML 10. Eur. J. Nucl. Med. Mol. Imaging 39, 1400-1408 (2012
127. Nguyen Q. D., et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase 3 selective molecular imaging. Clin. Cancer Res. 19, 3914-3924 (2013